 |
42 Diseases |  |
111 Trials |
|
111 Trials |  |
1691 News |  |
| «12...89101112131415161718...3132» |
- || Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, Review, Journal: Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches. (Pubmed Central) - Oct 30, 2021
Lipid and polymer-based drug-drug and drug-gene combinatorial nanocarriers delivering multiple chemotherapeutics simultaneously to desired site of action have been detailed. Finally, emerging opportunities such as pharmacological targets (immune check point and epigentic modulators) as well as gene-based modulation (siRNA/CRISPR/Cas9) and the nano-formulation challenges for effective treatment of both cancers have been explored.
- | pegylated liposomal doxorubicin / Generic mfg.
Journal: Acid-responsive HPMA copolymer-bradykinin conjugate enhances tumor-targeted delivery of nanomedicine. (Pubmed Central) - Oct 30, 2021
In addition, P-BK pre-treatment increased the tumor accumulation of pegylated liposomal doxorubicin (PLD) by approximately 3-fold...Collectively, P-BK pre-treatment improved intratumoral blood flow and augmented tumor accumulation of nanomedicine, thereby resulting in a significant suppression of tumor growth. Therefore, these findings demonstrate that P-BK is a potential concomitant drug for improving the tumor delivery of nanomedicines.
- || pegylated liposomal doxorubicin / Generic mfg., paclitaxel / Generic mfg.
Clinical, Retrospective data, Journal: The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials. (Pubmed Central) - Oct 28, 2021
In platinum-sensitive recurrent ovarian cancer, PLD plus carbo was more effective than PAC plus carbo, while in platinum-resistant or -refractory recurrent ovarian cancer, PLD exhibited similar survival to other monotherapies. Regarding side effects, PLD plus carbo and mono chemotherapy were both well tolerated.
- || pegylated liposomal doxorubicin / Generic mfg.
Clinical, Journal: Efficacy Of Pegylated Liposomal Doxorubicin-based Neoadjuvant Chemotherapy In Breast Cancer: A Single Center Experience. (Pubmed Central) - Oct 27, 2021
Higher histological grade was also associated high pCR rate (52.0% vs 40.0%). The use of PLD-containing chemotherapeutics in neoadjuvant settings might have benefits for non-metastatic operable breast cancer in Taiwanese females.
- ||| paclitaxel / Generic mfg.
Clinical, Journal, Adverse events: Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting. (Pubmed Central) - Oct 27, 2021
Existing trial data can be used to provide AE trajectories as illustrated here for ROC. These trajectories have utility in guiding treatment choice and potentially optimising AE management with novel therapies and treatment combinations.
- pegylated liposomal doxorubicin / Generic mfg.
Spatial, temporal and therapy dependent heterogeneity in transport phenotype of multiple liver metastases in murine breast cancer model (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_459;
Also, parental and selected two clonal cells exhibited different growth, response to PLD, and protein production in vitro . IVM imaging of individual liver metastasis over time using different cell lines revealed that relative fluorescent intensity of tracers transported inside/around tumor compared to that in the uninvolved tumor-free liver was more heterogeneous among parental cell derived tumors compared to clonal cells.
- |||||||||| nemvaleukin alfa (ALKS 4230) / Mural Oncology
New P3 trial, Combination therapy: Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (clinicaltrials.gov) - Oct 24, 2021
P3, N=376, Not yet recruiting, Sponsor: Alkermes, Inc.
- ||| Clinical, Next-generation sequencing: Thank you Dr. @JTrentMDPhD. Patient progressed on Gem-Docetaxel after 3 cycles. Pazopanib gave grade 3 diarrhea. Doxil also did not halt progression. Any benefit of trying lenvatinib in ur experience? Or any other drug that may help? NGS is pending. (Twitter) - Oct 22, 2021
- |||| pegylated liposomal doxorubicin / Generic mfg., Votrient (pazopanib) / Novartis
Next-generation sequencing: Any good ideas for extraskeletal osteosarcoma progressed after AIM-75 (response lasted 10 months), pazopanib, doxil, gem-tax? Has active Crohn's. NGS pend. ECOG 1 @JTrentMDPhD @jalivingston_md @bvantine1 @breelynwilkyMD @herbloong @NamBuiMD @RashmiChughMD @alegronchi @OncoAlert (Twitter) - Oct 22, 2021
- | Enrollment closed, IO biomarker: NRG-GY009: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Oct 18, 2021
P2/3, N=444, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
IVM imaging of individual liver metastasis over time using different cell lines revealed that relative fluorescent intensity of tracers transported inside/around tumor compared to that in the uninvolved tumor-free liver was more heterogeneous among parental cell derived tumors compared to clonal cells. Recruiting --> Active, not recruiting
- || doxorubicin hydrochloride / Generic mfg.
Clinical data, Preclinical, Journal: Injectable Drug Delivery Systems of Doxorubicin Revisited: In Vitro-In Vivo Relationships Using Human Clinical Data. (Pubmed Central) - Oct 14, 2021
The predictions required an estimation of the carrier half-life in blood circulation leading to considerable uncertainty. Still, the simulations narrow down the possible scenarios in the clinical evaluation of nanomedicines and provide a valuable addition to animal studies.
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) (clinicaltrials.gov) - Oct 13, 2021
P2, N=140, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Still, the simulations narrow down the possible scenarios in the clinical evaluation of nanomedicines and provide a valuable addition to animal studies. Not yet recruiting --> Recruiting
- pegylated liposomal doxorubicin / Generic mfg.
[VIRTUAL] FROM THE ENDOMETRIUM TO THE ATRIUM: A TREACHEROUS COURSE OF METASTASIS () - Oct 13, 2021 - Abstract #CHEST2021CHEST_926;
Treatment options include radiation therapy, chemotherapy with cisplatin followed by pegylated liposomal doxorubicin, and cryoablation of the mass. Cardiac involvement should be considered in patients presenting with dyspnea so that early targeted treatment may be initiated although its effects on outcomes need to be investigated.
- | pegylated liposomal doxorubicin / Generic mfg., vincristine / Generic mfg.
Journal: Synergistic co-loading of vincristine improved chemotherapeutic potential of Pegylated liposomal doxorubicin against triple negative breast cancer and non-small cell lung cancer. (Pubmed Central) - Oct 13, 2021
This carrier exhibited similar acute toxicity, pharmacokinetic and tissue distribution profiles with significant increase in tumor regression as compared to liposomal doxorubicin. These results indicate that co-encapsulation of vincristine into clinically used pegylated liposomal doxorubicin significantly improved in-vitro and in-vivo therapeutic efficacy against NSCLC and TNBC.
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Metastases: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (clinicaltrials.gov) - Oct 12, 2021
P3, N=270, Recruiting, Sponsor: Advenchen Laboratories, LLC
These results indicate that co-encapsulation of vincristine into clinically used pegylated liposomal doxorubicin significantly improved in-vitro and in-vivo therapeutic efficacy against NSCLC and TNBC. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
- |||| Elahere (mirvetuximab soravtansine-gynx) / AbbVie
Trial completion, Combination therapy, Metastases: KEYNOTE PN409: Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FR?) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Oct 12, 2021
P1b/2, N=264, Completed, Sponsor: ImmunoGen, Inc.
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Oct 2024 Active, not recruiting --> Completed
- || etrumadenant (AB928) / Arcus Biosci, Gilead
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: ARC-2: A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies (clinicaltrials.gov) - Oct 11, 2021
P1, N=35, Completed, Sponsor: Arcus Biosciences, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=214 --> 35 | Trial completion date: Jul 2022 --> Jul 2021 | Trial primary completion date: Feb 2022 --> Jul 2021
- || Avastin (bevacizumab) / Roche
Clinical, Journal, Real-world evidence: Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients. (Pubmed Central) - Oct 8, 2021
P=N/A
Clinical outcomes and tolerability with bevacizumab in this real-life setting are consistent with randomized trial results, notwithstanding differences in the treated patient population and treatment schedule. Clinical Trial Registration:ClinicalTrials.gov, Identifier NCT01832415.
- || pegylated liposomal doxorubicin / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Pegylated Liposomal Doxorubicin Versus Epirubicin as Adjuvant Therapy for Stage I-III Breast Cancer. (Pubmed Central) - Oct 8, 2021
Based on the large sample size and the long follow-up time of this study, we conclude that PLD has a similar anti-breast cancer efficacy as epirubicin while inducing lower level of cardiac toxicity in Han Chinese. This study suggests that PLD-based adjuvant chemotherapy could be a better option than epirubicin for breast cancer patients especially with existing cardiac disease.
- pegylated liposomal doxorubicin / Generic mfg.
Use of pegylated liposomal doxorubicin in patients with lymphoma and contraindications for anthracyclines () - Oct 7, 2021 - Abstract #DGHO2021DGHO_1066;
These patients represent a high-risk cohort associated with high mortality. Our results highlight CAD as less recognized risk factor for cardiotoxicity in patients with contraindications for anthracyclines.
- | pegylated liposomal doxorubicin / Generic mfg., lapatinib / Generic mfg.
Preclinical, Journal, Combination therapy: Development of a stable and high loaded liposomal formulation of lapatinib with enhanced therapeutic effects for breast cancer in combination with Caelyx®: In vitro and in vivo evaluations. (Pubmed Central) - Oct 7, 2021
Moreover, when it used in combination with liposomal doxorubicin, it extended the time to end from 22.4 ± 3.5 in the control group to 40 days in the TUBO cell line and from 29.2 ± 1.7 to 38.6 ± 2.2 days in 4T1 triple-negative breast cancer cell line, which reveals its promising effects on the survival of tumor-bearing mice. Our results indicated the need for further evaluations to understand liposomal lapatinib's potential effects on autophagy, apoptosis, and particularly on immune system cells.
- pegylated liposomal doxorubicin / Generic mfg.
[VIRTUAL] Neoadjuvant Acoustic Immune Priming With Low-Intensity Focused Ultrasound (LOFU) And Doxil For In Situ Tumor Vaccination In A Murine Triple-Negative Breast Cancer Model (Channel 3) - Oct 5, 2021 - Abstract #ACSCLINCON2021ACS_CLINCON_456;
Our results indicated the need for further evaluations to understand liposomal lapatinib's potential effects on autophagy, apoptosis, and particularly on immune system cells. Neoadjuvant acoustic immune priming of primary 4T1 tumors using LOFU and Doxil retained the survival benefit of chemotherapy but also yielded biologically significant immune activation of T cells in the TDLN, thereby acting as an in-situ tumor vaccine in a highly aggressive murine model of TNBC.
- ||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Clinical, P3 data, Journal, Combination therapy: Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34). (Pubmed Central) - Oct 3, 2021
P3
It is planned to randomize 664 patients. NCT03353831.
- ATRC-101 / Atreca
Preclinical evaluation of pegylated liposomal Doxorubicin or Doxorubicin with mATRC-101 in the EMT6 syngeneic mouse model (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_472;
Exposure to Doxorubicin or PLD in EMT6 tumor-bearing mice increased mATRC-101 immunoreactivity in the tumor, in a dose-dependent manner Moreover, mATRC-101 immunoreactivity in normal tissues was not influenced by Doxorubicin or PLD. Taken together, these findings support clinical evaluation of the combination of ATRC-101 and doxorubicin.
- Avastin (bevacizumab) / Roche
Effectiveness of bevacizumab in platinum-resistant recurrent epithelial ovarian cancer () - Oct 1, 2021 - Abstract #ESGO2021ESGO_853;
Conclusion* bevacizumab had the predictable safety profile, with better effectiveness than the published in clinical trials, reflecting the small number of patients included in our real-world unicentric series. Nevertheless, new molecular biomarkers and clinical trials urge to improve outcomes in platinum-resistant recurrent ovarian cancer patients in clinical practice.
- Bavencio (avelumab) / EMD Serono, Pfizer
Avelumab alone in platinum-resistant/refractory ovarian cancer: selected biomarker analyses from the JAVELIN Ovarian 200 trial () - Oct 1, 2021 - Abstract #ESGO2021ESGO_752;
Multivariable analyses are ongoing. Conclusion* Although JAVELIN Ovarian 200 did not meet its primary endpoints, these analyses indicate potential subgroups of patients who could have improved outcomes with immunotherapy alone and provide insights into the biology of PRROC that may inform future trials.
- Avastin (bevacizumab) / Roche
Could change in neoadjuvant chemotherapy regimen after 3 cycles lead to better outcomes in inoperable ovarian cancer? () - Oct 1, 2021 - Abstract #ESGO2021ESGO_737;
Though the numbers in each group were small, a change to bevacizumab-based regimen did not appear to improve outcomes. The ICON 8b study will provide further information regarding bevacizumab's role in the neoadjuvant setting.
- | Vynfinit (vintafolide) / Novartis
Enrollment change, Trial termination, Combination therapy: Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (clinicaltrials.gov) - Sep 30, 2021
P3, N=441, Terminated, Sponsor: Endocyte
The ICON 8b study will provide further information regarding bevacizumab's role in the neoadjuvant setting. N=640 --> 441 | Suspended --> Terminated; DSMB decision
- |||| pegylated liposomal doxorubicin / Generic mfg., carboplatin / Generic mfg., Lynparza (olaparib) / Merck (MSD), AstraZeneca
Clinical: We have a patient w/ gsBRIP1m platinum-sensitive relapsed ovarian cancer after good response (complete metabolic response by PET) to carboplatin-pegylated liposomal doxorubicin-beva on olaparib as maintenance therapy. The patient sustain complete response after 6 cycles. (Twitter) - Sep 29, 2021
- |||| pegylated liposomal doxorubicin / Generic mfg.
#Hand foot #syndrome HFS in Lipodox mediated in #MultipleMyeloma , #skincare utmost needed. @CCAD @AHDubai @DHA_Dubai @OmaniMOH @IndEmbDoha @ASCO @MDAndersonNews (Twitter) - Sep 29, 2021
- || batiraxcept (AVB-500) / Aravive
Trial primary completion date, Combination therapy: AVB500-OC-002: Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer (clinicaltrials.gov) - Sep 27, 2021
P1b/2, N=53, Active, not recruiting, Sponsor: Aravive, Inc.
N=640 --> 441 | Suspended --> Terminated; DSMB decision Trial primary completion date: Dec 2021 --> Jan 2021
- || azenosertib (ZN-c3) / Zentalis Pharma
Enrollment change, Combination therapy: ZN-c3-002: A Study of ZN-c3 in Patients With Ovarian Cancer (clinicaltrials.gov) - Sep 24, 2021
P1b, N=140, Recruiting, Sponsor: K-Group Beta
Trial primary completion date: Dec 2021 --> Jan 2021 N=100 --> 140
- ||| Elahere (mirvetuximab soravtansine-gynx) / ImmunoGen, Takeda
Enrollment open, Trial completion date, Trial primary completion date: MIROVA: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FR?) High Recurrent Ovarian Cancer (clinicaltrials.gov) - Sep 23, 2021
P2, N=136, Recruiting, Sponsor: AGO Research GmbH
N=100 --> 140 Not yet recruiting --> Recruiting | Trial completion date: Jan 2023 --> Dec 2023 | Trial primary completion date: Jan 2023 --> Dec 2023
- || Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Avastin (bevacizumab) / Roche
Clinical, Review, Journal: Managing recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on use of trabectedin. (Pubmed Central) - Sep 23, 2021
In cases of a rapidly growing tumor or need for symptomatic relief, the addition of bevacizumab should be considered. Patients with limited potential sensitivity to platinum, such as those with a platinum treatment-free interval of 6-12 months, may benefit from intercalation with trabectedin and pegylated liposomal doxorubicin to possibly restore platinum sensitivity.
- || Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
P1 data, Clinical Trial,Phase I, Journal: A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer. (Pubmed Central) - Sep 23, 2021
Trabectedin, in combination with PLD, may have clinical benefits in Japanese patients with relapsed advanced ovarian cancer. The recommended dosage of trabectedin for further study in this population is 1.1 mg/m once every 21 days.
- | pegylated liposomal doxorubicin / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial suspension, Surgery: Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer (clinicaltrials.gov) - Sep 21, 2021
P2, N=60, Suspended, Sponsor: Rutgers, The State University of New Jersey
The recommended dosage of trabectedin for further study in this population is 1.1 mg/m once every 21 days. Recruiting --> Suspended
- |||| pegylated liposomal doxorubicin / Generic mfg.
Any other oncologists remember the Doxil shortage about a decade ago? Turns out you can thank “an inexplicable bucket of urine” 🤦🏻♂️ (Twitter) - Sep 19, 2021
- ||| pegylated liposomal doxorubicin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Clinical, P3 data, Journal: Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial. (Pubmed Central) - Sep 19, 2021
Non-inferiority of 2 PLD dosing schedule was not confirmed because the trial was closed prematurely. However, recommendation of dose reduction of PLD should be based both on efficacy and safety.
- | Arzerra (ofatumumab) / Novartis, Genmab
Journal: Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity. (Pubmed Central) - Sep 16, 2021
However, recommendation of dose reduction of PLD should be based both on efficacy and safety. Our results indicate that this "double-attack" strategy using CD20 Ab-mPEG scFv and PLD can retain the tumor targeting (first attack) and confer PLD tumor-selectivity (second attack) to enhance PLD internalization and improve therapeutic efficacy in liquid tumors.
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer, Rituxan (rituximab) / Roche
Trial primary completion date: BV mini CHP: A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Sep 13, 2021
P2, N=24, Active, not recruiting, Sponsor: Patrick Reagan
Our results indicate that this "double-attack" strategy using CD20 Ab-mPEG scFv and PLD can retain the tumor targeting (first attack) and confer PLD tumor-selectivity (second attack) to enhance PLD internalization and improve therapeutic efficacy in liquid tumors. Trial primary completion date: Jun 2021 --> Jun 2022
- |||| pegylated liposomal doxorubicin / Generic mfg., Sylvant (siltuximab) / Jazz, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Castleman disease treatment in a Tweet Unicentric = Cut it out HHV8+Multicentric (MCD) = Rituximab+/-Doxil Idiopathic MCD = Siltuximab TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly) = Siltuximab or chemo POEMS associated MCD = IMiDs +/- auto BMT (Twitter) - Sep 11, 2021
- | pegylated liposomal doxorubicin / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy (clinicaltrials.gov) - Sep 10, 2021
P2, N=24, Active, not recruiting, Sponsor: University of Arizona
Trial primary completion date: Jun 2021 --> Jun 2022 Trial completion date: Jun 2021 --> Aug 2022 | Trial primary completion date: Dec 2018 --> Jul 2022
- ||| Imfinzi (durvalumab) / AstraZeneca, motolimod (VTX 2337) / BMS
Trial completion: Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - Sep 5, 2021
P1/2, N=53, Completed, Sponsor: Ludwig Institute for Cancer Research
Trial completion date: Jun 2021 --> Aug 2022 | Trial primary completion date: Dec 2018 --> Jul 2022 Active, not recruiting --> Completed
- | carboplatin / Generic mfg., decitabine / Generic mfg.
Trial completion date, Trial primary completion date: MITO29: Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. (clinicaltrials.gov) - Sep 5, 2021
P2, N=119, Recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Active, not recruiting --> Completed Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Jul 2021 --> Dec 2021
- || pegylated liposomal doxorubicin / Generic mfg.
Clinical, Journal: Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer. (Pubmed Central) - Sep 3, 2021
For patients who experience platinum-resistant and platinum-refractory relapse, the use of PLD may be acceptable because of the associated satisfactory efficacy, low frequency of AEs and high patient QOL. Moreover, a low CA125 level at baseline and a reduction in CA125 after the first cycle are predictive factors for satisfactory efficacy.
- || pegylated liposomal doxorubicin / Generic mfg.
Review, Journal: Targeted liposomal drug delivery: a nanoscience and biophysical perspective. (Pubmed Central) - Sep 1, 2021
Doxil is a representative example, which uses PEGylated liposomes to load doxorubicin for cancer therapy...Most of the examples are focused on targeting tumors or cancer cells. Finally, a few examples of commercialized formulations are described, and some future research opportunities are discussed.
- || CDX-1140 / Celldex, Mobista (CDX-301) / Celldex
New P1 trial, Combination therapy, Metastases: CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer (clinicaltrials.gov) - Aug 31, 2021
P1, N=45, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center
- | Talidox (doxorubicin liposomal) / Innomedica
Trial completion date, Trial primary completion date, Metastases: SAKK 65/16: TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 31, 2021
P1, N=30, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Finally, a few examples of commercialized formulations are described, and some future research opportunities are discussed. Trial completion date: Jun 2022 --> Oct 2023 | Trial primary completion date: Jun 2021 --> Oct 2023
- | Avastin (bevacizumab) / Roche
Preclinical, Journal, Tumor microenvironment, PD(L)-1 Biomarker, IO biomarker: Phytogalactolipid dLGG Inhibits Mouse Melanoma Brain Metastasis through Regulating Oxylipin Activity and Re-Programming Macrophage Polarity in the Tumor Microenvironment. (Pubmed Central) - Aug 28, 2021
An ex vivo 3D-culture assay further demonstrated that dLGG, 9,10-EpOME or 9,10-EpOME + 12,13-EpOME pretreatment attenuated B16BM4 cells invading brain tissue, and prevented microglia/macrophages infiltrating into the interface of melanoma plug and brain organ/tissue. In summary, this report provides a novel therapeutic strategy and mechanistic insights into phytogalactolipid dLGG for combating MBM.
- | Avastin (bevacizumab) / Roche
Biomarker, Retrospective data, Journal: Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study. (Pubmed Central) - Aug 28, 2021
We retrospectively analyzed data from 78 patients diagnosed with platinum-resistant OC, who underwent chemotherapy-based treatment with or without anti-angiogenic therapy at OncoHelp Oncology Center, Romania (January 2016-February 2021). Our study identified positive predictive factors for TTF related to histology (serous carcinoma subtype), anthropometry (age over 60 for patients treated with topotecan with or without bevacizumab), renal function (creatinine levels between 0.65 and 1 mg/dL for patients treated with regimens containing bevacizumab and pegylated liposomal doxorubicin) and treatment choice (bevacizumab in combination with pegylated liposomal doxorubicin or topotecan used from the first line and beyond).